Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real-world retrospective observational study (CTONG2004-ADV)

BACKGROUND: Camrelizumab plus chemotherapy have been approved as standards for the treatment of advanced non-small cell lung cancer (NSCLC) patients based on two phase III trials. However, clinical trial results may not be representative of the general population, as clinical trials often have speci...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Chong-Rui, Chen, Qixun, Zhou, Chengzhi, Wu, Lin, Li, Wen, Zhang, Huizhong, Li, Yongsheng, Xu, Fei, Xiong, Jianping, Wang, Qiming, Zhang, Haibo, Jiang, Yuequan, Yin, Haitao, Wu, Qingchen, Dai, Qiangsheng, Hu, Jian, Chen, Jianhua, Zhang, Jian, Wu, Gang, Yin, Jun, Zhao, Jianfu, Liu, Baogang, Shan, Jianzhen, Sheng, Liming, Chen, Qunqing, Han, Zhengxiang, Shi, Huaqiu, Liu, Yimin, Chen, Jun, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9903092/
https://www.ncbi.nlm.nih.gov/pubmed/36762057
http://dx.doi.org/10.21037/tlcr-22-852

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9903092/
https://www.ncbi.nlm.nih.gov/pubmed/36762057
http://dx.doi.org/10.21037/tlcr-22-852

Ejemplares similares